Journal: Molecular Oncology

Article Title: Drug sensitivity and resistance testing identifies PLK 1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors

doi: 10.1002/1878-0261.12086

Figure Lengend Snippet: Drug response heatmaps from CellTiter‐Glo ( CTG ) viability assay for seven MPNST cell lines, two normal human Schwann cell ( HSC ) cultures, and bone marrow (mean result from five healthy individuals). Drug responses for targeted drugs (excluding chemotherapeutic drugs) with a drug sensitivity score ( DSS CTG ) of 10, or more, in at least one MPNST cell line (A), and chemotherapeutic and other targeted drugs that have been used in clinical treatment of patients with MPNST (B). The same color coding and DSS gradient is used for both heatmaps.

Article Snippet: The HSC were maintained in Schwann cell medium (SCM, Cat. no. 1701, ScienCell) supplemented with Schwann cell growth supplement (SCGS, Cat. no. 1752, ScienCell) according to the suppliers’ recommendations.

Techniques: Viability Assay

Journal: Molecular Oncology

Article Title: Drug sensitivity and resistance testing identifies PLK 1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors

doi: 10.1002/1878-0261.12086

Figure Lengend Snippet: Identification of candidate drugs for MPNST treatment. Filtering steps used to identify drugs with high specificity and selectivity toward MPNST as compared to bone marrow and normal human Schwann cells ( HSC ) based on drug sensitivity scores from CellTiter‐Glo viability assay ( DSS CTG ).

Article Snippet: The HSC were maintained in Schwann cell medium (SCM, Cat. no. 1701, ScienCell) supplemented with Schwann cell growth supplement (SCGS, Cat. no. 1752, ScienCell) according to the suppliers’ recommendations.

Techniques: Viability Assay

Journal: Molecular Oncology

Article Title: Drug sensitivity and resistance testing identifies PLK 1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors

doi: 10.1002/1878-0261.12086

Figure Lengend Snippet: Expression of the drug targets PLK 1, RRM 1, and RRM 2 in MPNST cell lines and prognostic relevance in patients with MPNST . Normalized RPPA protein expression of PLK 1 in MPNST cell lines (median = 0 across 271 cancer‐relevant proteins) indicates an increased expression of PLK 1 in seven MPNST cell lines as compared to the mean of duplicate runs of normal Schwann cell HSC 1 (A). Regions of genomic gain (red) are not observed in the region on chromosome 16 harboring PLK 1 (16p12.2) in the tested MPNST cell lines, while regions of loss (blue) are observed in the two cell lines S1507‐2 and ST 8814 (B). Gene expression of PLK 1 is significantly higher in MPNST tumor samples as compared to benign neurofibromas (C, left panel), and high expression in MPNST is associated with high tumor grade and large tumor size (C, right panel). MPNST patients with high expression of PLK 1 in the tumor had worse outcome than patients with low expression, although not significantly at a 5% level (the P ‐value and hazard ratio ( HR ) for PLK 1 expression as a continuous variable in univariate Cox regression analysis for five‐year disease‐specific survival are shown) (D). The gene expression of gemcitabine target RRM 1 and its activator RRM 2 is significantly higher in MPNST tumor samples as compared to benign neurofibromas (E, left panel), and high expression of RRM 2 in MPNST is associated with high tumor grade and large tumor size (E, right panel). MPNST patients with high expression of RRM 2 in the tumor had significantly worse outcome than patients with low expression ( P ‐value and hazard ratio ( HR ) for gene expression as a continuous variable in univariate Cox regression analysis for 5‐year disease‐specific survival are shown) (F).

Article Snippet: The HSC were maintained in Schwann cell medium (SCM, Cat. no. 1701, ScienCell) supplemented with Schwann cell growth supplement (SCGS, Cat. no. 1752, ScienCell) according to the suppliers’ recommendations.

Techniques: Expressing, Gene Expression